The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials, International Immunopharmacology

Analysis (8 RCTs, n=6314) found tocilizumab does not provide a survival benefit for patients with COVID-19 (mortality at day 28 = 24.4% and 29.9% in tocilizumab and control groups, respectively), but it may help reduce the risk of mechanical ventilation and ICU admission.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Actemra | COVID-19 | Health